{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,14]],"date-time":"2025-12-14T16:10:19Z","timestamp":1765728619777,"version":"build-2065373602"},"reference-count":33,"publisher":"BMJ","issue":"19","funder":[{"DOI":"10.13039\/501100000272","name":"National Institute for Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Heart"],"accepted":{"date-parts":[[2017,3,15]]},"published-print":{"date-parts":[[2017,10]]},"abstract":"<jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>To determine whether patients with paroxysmal atrial fibrillation (AF) are less likely to be treated with anticoagulants than patients with persistent\/permanent AF and to investigate trends in treatment between 2000 and 2015. UK and European guidelines recommend that anticoagulants are offered to all patients with AF at increased risk of stroke, irrespective of AF type.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Sixteen sequential cross-sectional analyses from 2000 to 2015 were carried out with index dates on 1st of May each year. The data source was primary care data from 648 practices across the UK contributing to The Health Improvement Network database. All patients with a diagnosis of AF aged \u226535 years and registered for at least 1 year were included. The main outcome measure was prescription of anticoagulant medication.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The proportion of patients with AF with a diagnosis of paroxysmal AF increased from 7.4% (95% CI 7.0 to 7.8) in 2000 to 14.0% (95% CI 13.7 to 14.3) in 2015. Among patients with a CHADS<jats:sub>2<\/jats:sub> score of \u22651, between 2000 and 2015 the proportion prescribed anticoagulants increased from 18.8% (95% CI 16.4 to 21.4) to 56.2% (95% CI 55.0 to 57.3) and from 34.2% (95% CI 33.3 to 35.0) to 69.4% (95% CI 68.9 to 69.8) in patients with paroxysmal and other (persistent\/permanent) AF, respectively; RR for treatment of patients with paroxysmal AF compared with patients with other AF increased from 0.48 (95% CI 0.42 to 0.55) to 0.76 (95% CI 0.74 to 0.77). Adjusting for age, sex, Townsend score and presence or absence of contraindications had little effect on the results.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>In 2000, eligible patients with paroxysmal AF were half as likely to be treated with anticoagulants as patients with other AF; this has improved over time, but in 2015, eligible patients with paroxysmal AF were still around 20% less likely to be prescribed anticoagulant medication.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/heartjnl-2016-310927","type":"journal-article","created":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T20:40:22Z","timestamp":1496349622000},"page":"1502-1507","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":6,"title":["The treatment of paroxysmal atrial fibrillation in UK primary care"],"prefix":"10.1136","volume":"103","author":[{"given":"Andrea","family":"Isaew","sequence":"first","affiliation":[{"name":"Institute of Applied Health Research, University of Birmingham, Birmingham, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicola Jaime","family":"Adderley","sequence":"additional","affiliation":[{"name":"Institute of Applied Health Research, University of Birmingham, Birmingham, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronan","family":"Ryan","sequence":"additional","affiliation":[{"name":"Institute of Applied Health Research, University of Birmingham, Birmingham, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Fitzmaurice","sequence":"additional","affiliation":[{"name":"Institute of Applied Health Research, University of Birmingham, Birmingham, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tom","family":"Marshall","sequence":"additional","affiliation":[{"name":"Institute of Applied Health Research, University of Birmingham, Birmingham, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2017,6,1]]},"reference":[{"key":"2025092014275030000_103.19.1502.1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehs253"},{"key":"2025092014275030000_103.19.1502.2","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0b013e318214876d"},{"key":"2025092014275030000_103.19.1502.3","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(99)00489-1"},{"key":"2025092014275030000_103.19.1502.4","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehu359"},{"key":"2025092014275030000_103.19.1502.5","first-page":"632","article-title":"Distribution and risk profile of paroxysmal,\u00a0Persistent, and permanent atrial fibrillation in routine clinical practice","volume":"5","author":"Chiang","year":"2012","journal-title":"Insight From the Real-Life Global Survey Evaluating Patients With Atrial Fibrillation International Registry Circ Arrhythm Electrophysiol"},{"key":"2025092014275030000_103.19.1502.6","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehu307"},{"key":"2025092014275030000_103.19.1502.7","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.ijcard.2015.09.006","article-title":"Paroxysmal atrial fibrillation and the hazards of under-treatment","volume":"202","author":"Aronis","year":"2016","journal-title":"Int J Cardiol"},{"key":"2025092014275030000_103.19.1502.8","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2796.2007.01909.x"},{"key":"2025092014275030000_103.19.1502.9","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2261-5-20"},{"key":"2025092014275030000_103.19.1502.10","doi-asserted-by":"publisher","DOI":"10.1136\/heartjnl-2014-307043"},{"key":"2025092014275030000_103.19.1502.11","doi-asserted-by":"crossref","unstructured":"Aguilar MI , Hart R . Oral anticoagulants for preventing stroke in patients with non-valvular atrial fibrillation and no previous history of stroke or transient ischemic attacks. Cochrane Database of Systematic Reviews 2005(Issue 3). Art. No: CD001927.doi:10.1002\/14651858.CD001927.pub2","DOI":"10.1002\/14651858.CD006186"},{"key":"2025092014275030000_103.19.1502.12","doi-asserted-by":"crossref","unstructured":"Aguilar MI , Hart R , Pearce LA . Oral anticoagulants versus antiplatelet therapy for preventing stroke in patients with non-valvular atrial fibrillation and no history of stroke or transient ischemic attacks. Cochrane Database of Systematic Reviews 2007(Issue 3). Art. No: CD006186.doi:10.1002\/14651858.CD006186.pub2","DOI":"10.1002\/14651858.CD006186.pub2"},{"key":"2025092014275030000_103.19.1502.13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0905561"},{"key":"2025092014275030000_103.19.1502.14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1107039"},{"key":"2025092014275030000_103.19.1502.15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1009638"},{"key":"2025092014275030000_103.19.1502.16","unstructured":"Atrial fibrillation: the management of atrial fibrillation. Clinical guideline: methods, evidence and recommendations. London: National Institute for Health and Care Excellence (UK), 2014. National Clinical Guideline Centre."},{"key":"2025092014275030000_103.19.1502.17","unstructured":"Atrial fibrillation: the management of atrial fibrillation NICE clinical guideline 180. National Institute for Health and Care Excellence, 2014. National Institute for Health and Care Excellence."},{"key":"2025092014275030000_103.19.1502.18","doi-asserted-by":"crossref","unstructured":"January CT , Wann LS , Alpert JS , et al ; AHA\/ACC\/HRS guideline for the management of patients with atrial fibrillation, A report of the American college of cardiology\/American heart association task force on practice guidelines and the heart rhythm society, 2014.","DOI":"10.1161\/CIR.0000000000000041"},{"issue":"suppl 1","key":"2025092014275030000_103.19.1502.19","first-page":"54","article-title":"Patterns of antithrombotic therapy and type of atrial fibrillation: insights from the global anticoagulant registry in the FIELD (GARFIELD)","volume":"33","author":"Lip","year":"2012","journal-title":"Eur Heart J"},{"key":"2025092014275030000_103.19.1502.20","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0063479","article-title":"Risk profiles and antithrombotic treatment of patients newly diagnosed with atrial fibrillation at risk of stroke: perspectives from the international, observational, prospective GARFIELD registry","volume":"8","author":"Kakkar","year":"2013","journal-title":"PLoS One"},{"key":"2025092014275030000_103.19.1502.21","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(15)00283-1"},{"key":"2025092014275030000_103.19.1502.22","doi-asserted-by":"publisher","DOI":"10.1002\/pds.1688"},{"key":"2025092014275030000_103.19.1502.23","doi-asserted-by":"publisher","DOI":"10.1001\/jama.285.22.2864"},{"key":"2025092014275030000_103.19.1502.24","doi-asserted-by":"publisher","DOI":"10.1378\/chest.09-1584"},{"key":"2025092014275030000_103.19.1502.25","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1177\/1536867X0900900201","article-title":"Methods for estimating adjusted risk ratios","volume":"9","author":"Cummings","year":"2009","journal-title":"The Stata Journal"},{"key":"2025092014275030000_103.19.1502.26","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/j.amjmed.2014.11.035","article-title":"Differences in anticoagulant therapy prescription in patients with paroxysmal versus persistent atrial fibrillation","volume":"128","author":"Hsu","year":"2015","journal-title":"Am J Med"},{"key":"2025092014275030000_103.19.1502.27","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2005.06.077"},{"key":"2025092014275030000_103.19.1502.28","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.ijcard.2014.05.032","article-title":"Anticoagulant therapy is prescribed less often in paroxysmal atrial fibrillation regardless of thromboembolic risk: results from the Registry of Atrial Fibrillation To Investigate New Guidelines (RAFTING)","volume":"175","author":"Pipilis","year":"2014","journal-title":"Int J Cardiol"},{"key":"2025092014275030000_103.19.1502.29","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehi505"},{"key":"2025092014275030000_103.19.1502.30","doi-asserted-by":"publisher","DOI":"10.1093\/europace\/euv269"},{"key":"2025092014275030000_103.19.1502.31","unstructured":"Atrial Fibrillation Association and Anticoagulation Europe (UK). The AF report. atrial fibrillation: preventing a stroke crisis, 2011. Available at Last accessed. www.afa.org.uk and www.anticoagulationeurope.org. (18th October 2016)."},{"key":"2025092014275030000_103.19.1502.32","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2009.11.025"},{"key":"2025092014275030000_103.19.1502.33","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehq278"}],"container-title":["Heart"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/heartjnl-2016-310927","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T21:27:58Z","timestamp":1758403678000},"score":1,"resource":{"primary":{"URL":"https:\/\/heart.bmj.com\/lookup\/doi\/10.1136\/heartjnl-2016-310927"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,1]]},"references-count":33,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2017,9,11]]},"published-print":{"date-parts":[[2017,10]]}},"alternative-id":["10.1136\/heartjnl-2016-310927"],"URL":"https:\/\/doi.org\/10.1136\/heartjnl-2016-310927","relation":{},"ISSN":["1355-6037","1468-201X"],"issn-type":[{"type":"print","value":"1355-6037"},{"type":"electronic","value":"1468-201X"}],"subject":[],"published":{"date-parts":[[2017,6,1]]}}}